Plain-English translation of NCT07088458 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Hemophilia A research guide โThis is a research study that follows children with hemophilia A who are already taking damoctocog alfa pegol, a medicine that replaces missing clotting protein in the blood. Researchers want to learn how well this medication prevents bleeding episodes when used in real-world medical practice. By tracking your child's bleeding and treatment over time, doctors can better understand how effective the medication is for children like yours.
Hemophilia A is a genetic bleeding disorder that makes it hard for blood to clot, which can lead to dangerous bleeding after injuries or even spontaneous bleeding into joints. While this medication is approved and prescribed to help prevent these bleeding episodes, doctors want to learn more about how well it works in everyday practice to make sure children are getting the best possible care.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
Your child will continue taking the medication exactly as your doctor has already prescribed it โ nothing changes about their treatment. The study simply collects information about any bleeding episodes your child has, details about the medication doses given, and your child's overall health during routine doctor visits. This observation typically lasts for about one year, and all the data comes from your normal medical care visits.
AI-generated summary from trial data ยท Oct 27, 2026 ยท Not medical advice
United States
Brazil
Canada
Colombia